In a recent legal development, Teva Pharmaceuticals International GmbH is withdrawing its patent infringement case against Eli Lilly and Co. concerning a migraine medication. The motion for this action was carried out in a Massachusetts federal court.
This move comes on the heels of a decision by the Patent Trial and Appeal Board, which invalidated two patents linked to the migraine drug and its application. It must be noted that the particular details of these patents and the reasoning behind the Board’s decision were not immediately available for review.
Israeli multinational pharmaceutical company Teva is one of the largest generic drug manufacturers globally, whereas Eli Lilly, an American pharmaceutical company, is amongst the Fortune 500. The withdrawal of this case thus marks an important point in the patent litigation history of both companies.
The complete details of the court proceedings and further analysis of this case can be found in the original reporting by Law360. Legal professionals interested in following patent litigations and pharmaceutical industry cases may find this development of interest.